Depo-provera Ci Generic Name & Formulations
Medroxyprogesterone acetate 150mg/mL; IM inj.
Vials—1, 25; Prefilled syringe (1mL)—1 (w. needles); SubQ (prefilled syringe)—1 (w. needle)
Depo-provera Ci Indications
Limitations of Use
Not recommended as a long-term (eg, >2yrs) birth control method unless other options are considered inadequate.
Depo-provera Ci Dosage and Administration
Give by deep IM inj in the gluteal or deltoid muscle; rotate inj sites. 150mg every 3 months (13 weeks). Give 1st dose within 5 days of onset of normal menses (see full labeling for postpartum).
Pre-menarche: not applicable.
Depo-provera Ci Contraindications
Active thrombophlebitis. Thromboembolic disorders. Cerebrovascular disease. Breast carcinoma. Significant liver disease. Undiagnosed vaginal bleeding. Pregnancy.
Depo-provera Ci Boxed Warnings
Loss of bone mineral density.
Depo-provera Ci Warnings/Precautions
May lose significant bone mineral density (BMD). Evaluate BMD with long-term use or in adolescents. Risk for osteoporosis (eg, metabolic bone disease, anorexia, family history). Previous or family history of breast cancer (monitor closely). Ectopic pregnancy. History of depression; monitor for mood changes. Diabetes. Monitor conditions aggravated by fluid retention. Do pretreatment physical exam. Discontinue if jaundice or elevated transaminases, visual disturbances, migraine, or thrombotic disorders occur. Nursing mothers.
Depo-provera Ci Pharmacokinetics
Depo-provera Ci Interactions
May be antagonized by moderate or strong CYP3A4 inducers (eg, bosentan, efavirenz, etravirine, modafinil, rifampin, carbamazepine, phenytoin, phenobarbital, mitotane, St. John's wort, others); avoid. May reduce bone mass with anticonvulsants, corticosteroids; avoid alcohol, tobacco. May be affected by protease inhibitors, NNRTIs. May affect results of lab tests (eg, coagulation factors, lipids, glucose tolerance, and binding proteins); see full labeling.
Depo-provera Ci Adverse Reactions
Dysfunctional uterine bleeding, headache, increased weight, amenorrhea, inj site reactions, vaginitis, abdominal pain, UTIs, acne; decreased BMD, anaphylaxis.
Depo-provera Ci Clinical Trials
Depo-provera Ci Note
Depo-provera Ci Patient Counseling